JPRN-jRCT2031220265
Active, not recruiting
Phase 3
A Phase III, multicenter, open-label study to evaluate the efficacy and safety of NRL-1 intranasally administered in Japanese pediatric patients with or at risk for status epilepticus
akagawa Eiji0 sites15 target enrollmentAugust 11, 2022
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- akagawa Eiji
- Enrollment
- 15
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Japanese pediatric patients with or at risk for status epilepticus
Exclusion Criteria
- •Patients who in the opinion of the Investigator or Subinvestigator, previously failed to respond to diazepam injected within 5 minutes after onset of seizures
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 3
Phase III study of intramuscular TAK-816 in healthy infantsJPRN-jRCT2080222404TAKEDA PHARMACEUTICAL COMPANY LTD.30
Active, not recruiting
Phase 3
A large, multi-clinic study to evaluate contraceptive efficacy and safety of depot medroxyprogesterone acetate (150 mg/ml) injected under the skin every 6 monthsContraception for up to 6 monthsPregnancy and ChildbirthISRCTN62695528Family Health International 360750
Active, not recruiting
Phase 1
Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals? influenza vaccine when administered in children who previously participated in study 115345Healthy volunteers (Immunization against influenza A and B in children aged 18 to 47 months)MedDRA version: 14.1Level: LLTClassification code 10022001Term: Influenza (epidemic)System Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10022003Term: Influenza B virus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10022002Term: Influenza A virus infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2012-001230-34-ESGlaxoSmithKline S.A.470
Active, not recruiting
Phase 1
Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ influenza vaccine when administered in children who previously participated in study 115345EUCTR2012-001230-34-PLGlaxoSmithKline Biologicals452
Active, not recruiting
Not Applicable
Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ influenza vaccine when administered in children who previously participated in study 115345Healthy volunteers (Immunization against influenza A and B in children aged 18 to 47 months)MedDRA version: 14.1Level: LLTClassification code 10022002Term: Influenza A virus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10022001Term: Influenza (epidemic)System Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10022003Term: Influenza B virus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2012-001230-34-CZGlaxoSmithKline Biologicals452